Critical Path to TB Drug Regimens (CPTR) is a global public-private-partnership focused on accelerating the delivery of novel drug regimens and diagnostics for tuberculosis. This critical work is enabled by a global data sharing initiative, led by the Critical Path Institute in partnership with key organizations which include the WHO, TB Alliance, FIND and multiple data contributors. This partnership is funded by the Bill & Melinda Gates Foundation. This multi-faceted data-sharing platform will be leveraged to inform the development of TB clinical trial modelling and simulation tools that will be made publicly available to those designing trials. The Relational Sequencing Data Platform for TB (ReSeqTB) will provide diagnostic developers, clinicians and the global research community access to validated, standardized data on multidrug-resistant TB mutations associated with phenotypic resistance to support researchers in developing rapid drug susceptibility tests for existing and emerging TB drugs. Such tests are crucial to researchers for creating and evaluating potential new therapies, and to clinicians for selecting effective TB treatments.